{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:07:51Z","timestamp":1792012071667,"version":"4.4.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Lenvatinib is a type I tyrosine kinase inhibitor exhibiting powerful antiangiogenic activity in cancer therapy. Displaying activity in multiple solid tumors, it has been approved in differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma as single agent or in combination. In addition, lenvatinib has shown promise in several other tumor types including medullary, anaplastic thyroid, adenoid cystic, and endometrial cancer. Exploring synergy between angiogenic and immune checkpoint inhibitors, the lenvatinib\/pembrolizumab combination is poised to become the next pair of active drugs in endometrial, lung, and gastrointestinal malignancies. Despite robust activity, the drug can be difficult to tolerate. Optimization of dose and biomarkers for prediction of efficacy and toxicities will be of great help.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0407","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T18:45:16Z","timestamp":1571078716000},"page":"e302-e310","source":"Crossref","is-referenced-by-count":103,"title":["Lenvatinib in Management of Solid Tumors"],"prefix":"10.1093","volume":"25","author":[{"given":"Zhonglin","family":"Hao","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Kentucky College of Medicine, Lexington, Kentucky, USA"},{"name":"Markey Cancer Center, Lexington, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Kentucky College of Medicine, Lexington, Kentucky, USA"},{"name":"Markey Cancer Center, Lexington, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,14]]},"reference":[{"key":"2021122510123509100_R1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0968-0004(00)01712-6","article-title":"The regulation of protein function by multisite phosphorylation\u2014A 25 year update","volume":"25","author":"Cohen","year":"2000","journal-title":"Trends Biochem Sci"},{"key":"2021122510123509100_R2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1146\/annurev.biochem.78.070907.103047","article-title":"The chemical biology of protein phosphorylation","volume":"78","author":"Tarrant","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"2021122510123509100_R3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.8052857","article-title":"Transformation of mammalian cells by constitutively active map kinase kinase","volume":"265","author":"Mansour","year":"1994","journal-title":"Science"},{"key":"2021122510123509100_R4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.gde.2006.12.008","article-title":"Cell cycle kinases in cancer","volume":"17","author":"Malumbres","year":"2007","journal-title":"Curr Opin Genet Dev"},{"key":"2021122510123509100_R5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nchembio.297","article-title":"The (un)targeted cancer kinome","volume":"6","author":"Fedorov","year":"2010","journal-title":"Nat Chem Biol"},{"key":"2021122510123509100_R6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/ar0201207","article-title":"Protein kinase inhibitors as a therapeutic modality","volume":"36","author":"Levitzki","year":"2003","journal-title":"Acc Chem Res"},{"key":"2021122510123509100_R7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"key":"2021122510123509100_R8","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122510123509100_R9","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1158\/1078-0432.CCR-09-1980","article-title":"E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles","volume":"15","author":"Ikuta","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122510123509100_R10","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ijc.25922","article-title":"Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts","volume":"129","author":"Bruheim","year":"2011","journal-title":"Int J Cancer"},{"key":"2021122510123509100_R11","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s13318-017-0403-4","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor","volume":"42","author":"Hussein","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2021122510123509100_R12","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1158\/1535-7163.MCT-10-0707","article-title":"E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor","volume":"10","author":"Ogino","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2021122510123509100_R13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/1471-2407-11-309","article-title":"E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion","volume":"11","author":"Glen","year":"2011","journal-title":"BMC Cancer"},{"key":"2021122510123509100_R14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/ml500394m","article-title":"Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization","volume":"6","author":"Okamoto","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"2021122510123509100_R15","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: Focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr Pharm Des"},{"key":"2021122510123509100_R16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5414\/CP201937","article-title":"Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (e7080) in healthy volunteers","volume":"52","author":"Shumaker","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2021122510123509100_R17","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00280-015-2899-0","article-title":"A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in japanese patients with advanced solid tumors","volume":"76","author":"Nakamichi","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122510123509100_R18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bcp.12907","article-title":"Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer","volume":"81","author":"Gupta","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2021122510123509100_R19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jcph.398","article-title":"Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration","volume":"55","author":"Shumaker","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"2021122510123509100_R20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10637-014-0181-7","article-title":"Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas","volume":"33","author":"Dubbelman","year":"2015","journal-title":"Invest New Drugs"},{"key":"2021122510123509100_R21","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/cncr.29395","article-title":"A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment","volume":"121","author":"Cabanillas","year":"2015","journal-title":"Cancer"},{"key":"2021122510123509100_R22","first-page":"129","article-title":"Multikinase inhibitors in the treatment of thyroid cancer: Specific role of lenvatinib","volume":"8","author":"Stjepanovic","year":"2014","journal-title":"Biologics"},{"key":"2021122510123509100_R23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510123509100_R24","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1158\/1078-0432.CCR-15-1377","article-title":"FDA approval summary: Lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer","volume":"21","author":"Nair","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122510123509100_R25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett"},{"key":"2021122510123509100_R26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122510123509100_R27","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0","article-title":"Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991","volume":"79","author":"Gilliland","year":"1997","journal-title":"Cancer"},{"key":"2021122510123509100_R28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/thy.2016.0395","article-title":"Patterns of treatment failure in anaplastic thyroid carcinoma","volume":"27","author":"Rao","year":"2017","journal-title":"Thyroid"},{"key":"2021122510123509100_R29","first-page":"1330","article-title":"Anaplastic thyroid carcinoma","volume":"103","author":"Kebebew","year":"2005","journal-title":"Treatment outcome and prognostic factors. Cancer"},{"key":"2021122510123509100_R30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122510123509100_R31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/thy.2016.0076","article-title":"Real-time genomic characterization utilizing circulating cell-free DNA in patients with anaplastic thyroid carcinoma","volume":"27","author":"Sandulache","year":"2017","journal-title":"Thyroid"},{"key":"2021122510123509100_R32","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"2021122510123509100_R33","first-page":"7271","article-title":"Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study","volume":"16","author":"Iwasaki","year":"2018","journal-title":"Oncol Lett"},{"key":"2021122510123509100_R34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000485972","article-title":"Lenvatinib for anaplastic thyroid cancer and lenvatinib-induced thyroid dysfunction","volume":"7","author":"Koyama","year":"2018","journal-title":"Eur Thyroid J"},{"key":"2021122510123509100_R35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fonc.2017.00025","article-title":"Lenvatinib for anaplastic thyroid cancer","volume":"7","author":"Tahara","year":"2017","journal-title":"Front Oncol"},{"key":"2021122510123509100_R36","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2021122510123509100_R37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00280-018-3657-x","article-title":"Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer","volume":"82","author":"Yamazaki","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122510123509100_R38","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1158\/1078-0432.CCR-15-1354","article-title":"Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"22","author":"Ikeda","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122510123509100_R39","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda","year":"2017","journal-title":"J Gastroenterol"},{"key":"2021122510123509100_R40","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"2021122510123509100_R41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/JHC.S168953","article-title":"Lenvatinib for the treatment of unresectable hepatocellular carcinoma: Evidence to date","volume":"6","author":"Personeni","year":"2019","journal-title":"J Hepatocell Carcinoma"},{"key":"2021122510123509100_R42","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/bjc.2012.154","article-title":"A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours","volume":"106","author":"Boss","year":"2012","journal-title":"Br J Cancer"},{"key":"2021122510123509100_R43","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-14-3063","article-title":"Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma","volume":"21","author":"Hong","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122510123509100_R44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-013-2339-y","article-title":"A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)","volume":"73","author":"Molina","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122510123509100_R45","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122510123509100_R46","first-page":"687","volume":"6","author":"FDA approves drug combo for kidney cancer","year":"2016","journal-title":"Cancer Discov"},{"key":"2021122510123509100_R47","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","author":"Tchekmedyian","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122510123509100_R48","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-10-2638","article-title":"Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors","volume":"17","author":"Yamada","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122510123509100_R49","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/jcph.917","article-title":"Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses","volume":"57","author":"Tamai","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2021122510123509100_R50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12020-017-1233-5","article-title":"Incidence and timing of common adverse events in lenvatinib-treated patients from the select trial and their association with survival outcomes","volume":"56","author":"Haddad","year":"2017","journal-title":"Endocrine"},{"key":"2021122510123509100_R51","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1002\/cncr.31344","article-title":"Treatment-emergent hypertension and efficacy in the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)","volume":"124","author":"Wirth","year":"2018","journal-title":"Cancer"},{"key":"2021122510123509100_R52","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","article-title":"Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial","volume":"35","author":"Brose","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122510123509100_R53","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122510123509100_R54","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/ijc.25863","article-title":"Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination","volume":"129","author":"Bose","year":"2011","journal-title":"Int J Cancer"},{"key":"2021122510123509100_R55","article-title":"Angiogenesis and anti-tumor immunity in the tumor microenvironment: Opportunities for synergism in intervention","volume":"3","author":"Lemmon","year":"2017","journal-title":"J Nat Sci"},{"key":"2021122510123509100_R56","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2021122510123509100_R57","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122510123509100_R58","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122510123509100_R59","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: A single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021122510123509100_R60","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","article-title":"Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma","volume":"6","author":"Iyer","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2021122510123509100_R61","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021122510123509100_R62","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.4158\/EP171822.OR","article-title":"Optimizing lenvatinib therapy in patients with metastatic radioactive iodine-resistant differentiated thyroid cancers","volume":"23","author":"Jasim","year":"2017","journal-title":"Endocr Pract"},{"key":"2021122510123509100_R63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.10.002","article-title":"Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Tahara","year":"2019","journal-title":"Eur J Cancer"},{"key":"2021122510123509100_R64","first-page":"98","article-title":"Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer","volume":"e14774","author":"Yamazaki","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2021122510123509100_R65","doi-asserted-by":"crossref","DOI":"10.1016\/j.wneu.2017.08.017","article-title":"Unusual magnetic resonance imaging findings of a glioblastoma arising during treatment with lenvatinib for thyroid cancer","volume":"107","author":"Arai","year":"2017","journal-title":"World Neurosurg"},{"key":"2021122510123509100_R66","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1158\/1535-7163.MCT-18-0695","article-title":"Distribution and activity of lenvatinib in brain tumor models of human anaplastic thyroid cancer cells in severe combined immune deficient mice","volume":"18","author":"Wang","year":"2019","journal-title":"Mol Cancer Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0407","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/e302\/41919272\/oncolo_25_2_e302.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/e302\/41919272\/oncolo_25_2_e302.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:14:05Z","timestamp":1640427245000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/2\/e302\/6443329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,14]]},"references-count":66,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,14]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0407","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,1]]},"published":{"date-parts":[[2019,10,14]]}}}